Company
Patrys Ltd
ASX:PAB
Based in Melbourne, Australia, Patrys is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications.
68 stories
Patrys strengthens board with appointment of pharma executive as chairman
Dr Charmaine Gittleson’s expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research to strategic planning and executive management.
Patrys' preclinical data demonstrates PAT-DX3 can cross blood-brain barrier 3-4 times more effectively than control
“These properties open up a range of applications for using deoxymabs to deliver small molecule therapeutics and gene editing technologies directed to various neurological targets and conditions," said CEO and MD Dr James Campbell.
Patrys hunts for new chair as company secretary takes on extra duties
The company has appointed Stefan Ross as a non-executive director and is also on the hunt for a new chair following John Read’s retirement.
Patrys readies PAT-DX1 for the clinic after passing specification tests
The company is putting in the groundwork ahead of a Phase 1 clinical trial, which is slated to kick off in the second half of next year.
Patrys grateful for new $100,000 research grant for deoxymabs in metastatic breast cancer
ONJCRI’s Translational Breast Cancer Program and Metastasis Research Laboratory head Professor Robin Anderson will lead the study into incorporating the cell-penetrating antibodies, PAT-DX1 and PAT-DX3, into new metastatic breast cancer tre
Patrys ticks off successful animal study of cancer-tackling asset PAT-DX1, is on course for clinical trials
The company’s asset PAT-DX1 was shown to significantly improve survival in an animal model of an aggressive and almost universally lethal brain cancer when combined with radiation therapy.
Patrys non-executive chair retires following completion of PAT-DX1 engineering, citing “new chapter” for the company
“With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company," Outoing chair John
Patrys winds up successful engineering run to produce large-scale quantities of clinical grade PAT-DX1
The company believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.
Patrys welcomes publication supporting new mechanism for asset PAT-DX1 in cancer metastasis
The company is buoyed by a peer-reviewed publication that reports that Patrys’ deoxymab antibody PAT-DX1 suppresses the formation of neutrophil extracellular traps, which have been implicated in the progression and metastasis of some cancer
Patrys receives $250,000 in funding to support brain cancer research
“This is one of our most exciting collaborations to date. Professor Johns and his team are leaders in brain cancer translational research in Australia and have numerous international connections," Patrys CEO and managing director Dr James C
Patrys’ new VP to drive deoxymab technology at pivotal time
“This is an important and exciting appointment for Patrys as we prepare for the first in human studies of PATDX1 in mid-2023, ideally followed by other deoxymab assets,” Patrys CEO and MD Dr James Campbell said.
Patrys establishes stable cell line to produce PAT-DX3 anti-cancer candidate
“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3,” says CEO & MD.
Patrys encouraged by latest headlines on antibody drug conjugates
In a newsletter on Tuesday, CEO and managing director Dr James Campbell outlined the growing upside in the ADC space — and how Patrys is poised to capitalise on momentum.
Patrys completes first engineering run of lead asset PAT-DX1
The company's wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has also received a $1,188,581 R&D Tax Incentive Refund for the 2020/2021 financial year.
Patrys closes out year having achieved “new heights” with critical validation of R&D program
“Having two assets on the path to the clinic is a very exciting place to be, and makes Patrys a much more robust investment opportunity. I personally can’t wait to see what we learn and I encourage you to stay tuned for our updates," says C
Patrys raising A$7.8 million to expand business development
“Based on the promising data we have seen for PAT-DX3 since we announced it 12 months ago, we believe there are a range of very attractive potential applications for this deoxymab that will significantly expand opportunities for internal de
Patrys buoyed by strong drug pipeline and robust balance sheet as it strides toward new year
“This quarter has delivered a period of significant momentum for Patrys. We have continued to build the portfolio of data for deoxymabs which has further expanded the broad and promising utility for our antibody assets in addition to meetin
Patrys' deoxymab conjugate increases breast cancer survival rate in animal model
“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival," says CEO.
Patrys raising $7.3 million to fund Deoxymab program through first-in-man studies
The funds raised through the placement and rights issue will position the company to effectively leverage the wide range of therapeutic opportunities provided by its unique Deoxymab platform.
Patrys shares rise after positive pre-clinical results in suppressing breast cancer brain metastases
After four weeks of treatment with PAT-DX1, treated mice showed 93% less brain metastasis than untreated mice.
Caeneus Minerals is the ASX Most Active at noon, King River Copper not far behind
There is heavy trading activity in the small cap sector today.
Patrys up 32% on progress with drug candidates targeting aggressive brain cancer
Two pre-clinical drug candidates found to effectively target and kill human glioblastoma cancer stem cells in vitro.
Patrys secures $3.5 million for anti-cancer therapies
The single tranche placement will see new shares issued priced at 3.4 cents.
Patrys a leading ASX gainer on brain tumour trial breakthrough
Shares rise 80% to a 12-month high on strong volume.
Patrys' shares halted
The halt will remain in place until Monday 15th January 2018.
Patrys wins another U.S. patent for its unique cancer antibody
The antibody has shown great promise in laboratory and animal testing.
Patrys sits among Leading ASX % Gainers in afternoon trade
Patrys shares are climbing higher today following last weeks news.
Patrys is the ASX Most Traded, but losing momentum
Patrys shares are fading today, but the stock is still a three-bagger over past two days.
Patrys takes another gong riding near the top of the ASX Most Active
Patrys has traded over 84 million shares intra-day.
Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers
Patrys has traded over 27 million shares in the first hour of the session.